Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

Abstract

Malignant melanoma is a prime example of cancers that respond poorly to various treatment modalities including chemotherapy1. A number of chemotherapeutic agents have been shown recently to act by inducing apoptosis, a type of cell death antagonized by the bcl-2 gene2. Human melanoma expresses Bcl-2 in up to 90% of all cases3–7. In the present study we demonstrate that bcl-2 antisense oligonucleotide treatment improves the chemo-sensitivity of human melanoma grown in severe combined im-munodeficient (SCID) mice. Our findings suggest that reduction of Bcl-2 in melanoma, and possibly also in a variety of other tumors, may be a novel and rational approach to improve chemosensitivity and treatment outcome.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Boring, C.C., Squires, T.S., Tong, T. & Montgomery, S. Cancer statistics 1994. CA: Cancer J. Clinic 44, 7–26 (1994).

    CAS  Google Scholar 

  2. 2

    Hickman, J.A. Apoptosis and chemotherapy resistance. Eur. J. Cancer 32A, 921–926 (1996).

    CAS  Article  Google Scholar 

  3. 3

    Cerroni, L., Soyer, H.P. & Kerl, H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am. J. Dermatopathol. 17, 7–11 (1995).

    CAS  Article  Google Scholar 

  4. 4

    Morales-Ducret, C.R.J., van deRijn, M., LeBrun, D.P. & Smoller, B.R. bcl-2 expression in primary malignancies of the skin. Arch. Dermatol. 131, 909–918 (1995).

    CAS  Article  Google Scholar 

  5. 5

    Plettenberg, A. et al. Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. Am. J. Pathol. 146, 651–659 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  6. 6

    Tron, V.A. et al. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am. J. Pathol. 146, 643–650 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  7. 7

    Grover, R. & Wilson, C.D. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur. J. Surg. Oncol. 22, 347–349 (1996).

    CAS  Article  Google Scholar 

  8. 8

    Stein, C.A. & Cheng, Y.-C. Antisense oligonucleotides as therapeutic agents–Is the bullet really magical? Science 261, 1004–1012 (1993).

    CAS  Article  Google Scholar 

  9. 9

    Stein, C.A. Does antisense exist? Nature Med. 1, 1119–1121 (1995).

    CAS  Article  Google Scholar 

  10. 10

    Christoffersen, R.E. Translating genomics information into therapeutics: A key role for oligonucleotides. Nature Biotechnol. 15, 483–484 (1997).

    CAS  Article  Google Scholar 

  11. 11

    Monia, B.P., Johnston, J.F., Geiger, T., Muller, M. & Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2, 668–675 (1996).

    CAS  Article  Google Scholar 

  12. 12

    Comis, R.L. DTIC (NSC-45388) in malignant melanoma: A perspective. Cancer Treat Rep. 60, 165–176 (1976).

    CAS  PubMed  Google Scholar 

  13. 13

    Henry, S.P., Monteith, D. & Levin, A.A. Antisense oligonucleotide inhibitors for the treatment of cancer. 2. Toxicological properties of phosphorothioate oligonucleotides. Anti-Cancer Drug Des. 12, 395–408 (1997).

    CAS  Google Scholar 

  14. 14

    Krieg, A.M. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546–549 (1995).

    CAS  Article  Google Scholar 

  15. 15

    Wooldridge, J.E., Ballas, Z., Krieg, A.M. & Weiner, G.J. Immunostimulatory oligonucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood, 89, 2994–2998 (1997).

    CAS  PubMed  Google Scholar 

  16. 16

    Webb, A. et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349, 1137–1141 (1997).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jansen, B., Schlagbauer-Wadl, H., Brown, B. et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4, 232–234 (1998). https://doi.org/10.1038/nm0298-232

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing